The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Ryght AI tackles these hurdles with its AI Site Twin platform
Clinical trial enrollment has long been a bottleneck in drug development
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Subscribe To Our Newsletter & Stay Updated
